Compare ZURA & TMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZURA | TMS |
|---|---|---|
| Founded | 2022 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.4M | 527.4M |
| IPO Year | 2021 | 2025 |
| Metric | ZURA | TMS |
|---|---|---|
| Price | $4.09 | $6.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $18.00 | $12.88 |
| AVG Volume (30 Days) | ★ 1.8M | 100.9K |
| Earning Date | 11-12-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $41.60 |
| Revenue Next Year | N/A | $71.01 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.15 | $5.04 |
| 52 Week High | $7.25 | $10.10 |
| Indicator | ZURA | TMS |
|---|---|---|
| Relative Strength Index (RSI) | 36.17 | 41.03 |
| Support Level | $3.90 | $5.31 |
| Resistance Level | $5.87 | $9.58 |
| Average True Range (ATR) | 0.29 | 0.84 |
| MACD | 0.03 | -0.17 |
| Stochastic Oscillator | 34.37 | 7.60 |
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
Teamshares Inc is a tech-enabled company that acquires and operates small and medium-sized businesses. It uses a software platform to support activities across the acquisition lifecycle, including sourcing, evaluation, and transaction execution. After acquisition, the platform is used to integrate financial and operational data and to monitor performance across its portfolio companies. The company has two reportable segments: Small Business Acquisitions and Real Estate. The majority of revenue is derived from the Small Business Acquisitions, which includes all of the Operating Subsidiaries owned by the company.